Clinical research
Clinical Trials
Dr. Madhumitha Reddy, D.O., is proud to participate in clinical research that helps advance the future of urologic care. Eligible patients may have access to investigational treatments through carefully monitored clinical trials.
Current research focus
Areas of active investigation
Every study has specific eligibility requirements based on your diagnosis, prior treatments, and overall health. The best way to find out whether you may qualify is to speak with our clinical research team.
Prostate Cancer
Studies exploring new ways to manage or treat prostate cancer, including options that may help eligible patients delay progression or reduce treatment burden.
Non-Muscle Invasive Bladder Cancer
Research focused on reducing recurrence and preserving bladder function for patients with non-muscle invasive bladder cancer.
Recurrent Urinary Tract Infections
Investigational approaches aimed at lowering how often UTIs return and improving comfort between episodes.
Active trials
Explore our current clinical trials
Click any card to read a plain-language summary. For full eligibility criteria and study details, please contact our office.
A study for eligible patients with prostate cancer, evaluating whether an investigational treatment approach can help delay disease progression compared with current standard care.
Learn more on ClinicalTrials.gov — ABLE-32 (NCT06510374), opens in a new tabA study of an investigational long-acting hormone therapy for advanced prostate cancer, looking at how well it controls testosterone levels and how patients tolerate treatment.
Learn more on ClinicalTrials.gov — Debio 4228-201 (NCT06395753), opens in a new tabAn expanded access program that may allow eligible prostate cancer patients to receive an investigational therapy outside of a standard randomized trial.
Learn more on ClinicalTrials.gov — CRETO-EAP (NCT06443944), opens in a new tabA study of an investigational bladder-instilled immunotherapy for non-muscle invasive bladder cancer, including patients whose disease returned after BCG treatment.
Learn more on ClinicalTrials.gov — CORE-008 (NCT06567743), opens in a new tabA study in which an investigational gel is placed in the bladder at the time of TURBT surgery, to see whether it can lower the chance of recurrent papillary bladder tumors.
Learn more on ClinicalTrials.gov — STM-416-01 (NCT05710848), opens in a new tabA follow-on study of the same investigational surgical gel therapy for non-muscle invasive bladder cancer, evaluating safety and how well it prevents recurrence.
Learn more on ClinicalTrials.gov — STM-416p-201 (NCT06450106), opens in a new tabA study of an investigational immune-activating therapy delivered into the bladder for patients with non-muscle invasive bladder cancer.
Learn more on ClinicalTrials.gov — ResQ132-EX NMIBC (NCT06810141), opens in a new tabAn early-phase study of an investigational intravesical (in-bladder) medication for non-muscle invasive bladder cancer, focused on safety and tumor response.
Learn more on ClinicalTrials.gov — UGN-501-101 (NCT07725796), opens in a new tabA study of EG-70, an investigational non-viral gene therapy given into the bladder, for patients with BCG-unresponsive non-muscle invasive bladder cancer.
Learn more on ClinicalTrials.gov — LEGEND Study — EG-70 (NCT04752722), opens in a new tabA study of an investigational bacteriophage-based therapy for urinary tract infections caused by E. coli, aimed at clearing infection and reducing recurrence.
Learn more on ClinicalTrials.gov — ELIMINATE Trial — LBP-EC01 (NCT05488340), opens in a new tabTake the next step
Interested in Participating?
Our clinical team can help determine whether you may qualify for an active clinical trial. You can request a consultation online or call us directly.
These summaries are intended for patient education only and do not include complete eligibility requirements. Participation depends on your diagnosis, previous treatments, and overall health. Please contact our office to discuss your individual situation.